"would take advantage of strong pressure on Sanofi to buy, a target price of 57 € " (Caja Madrid).
"After failing to reach agreement with the company, Sanofi has launched a public tender offer by Genzyme on 18500 Mln. They are $ 69 per share in cash. It is a 2% listed below where the company, which had risen 30% in mid-July when it was first rumored news. would take advantage of strong pressure on the value to buy with a target price of 57 EUR. Genzyme is a biotechnology-oriented genetic diseases, but increasingly diversifying into other diseases. You have about 15 molecules in development. We believe synergies of 2% for the new company. Now that the management team that took office early last year has gained credibility, make a larger purchase that could not wait until then. We believe it makes sense strategically and allowing it to increase its pipeline at a time of consolidation of the sector subject to patent term for drugs. As in all corporate operations, volatilities and Sanofi would suffer additional pressure on its price by the size of this acquisition, we believe that positive, with around 50% of their income in the U.S. and 31% in Europe. Would take advantage of strong pressure the value to buy with a target price of 57 EUR. " Tags: Recommendations /
http://www.consensodelmercado.es/index.php/noticias/35-noticias / 1019-would take advantage of high-pressure-en sanofi-to-buy-with-one-price-target-of-57-cajamadrid
-------------- ------------
WHAT WE MADE TO WOMEN WHO TAKE:
"Agreal / veralipride IN SPAIN NO
SHALL
"impunity".
THEN:
"BOTH STAFF LAYOFFS"
MANY "ARE."
0 comments:
Post a Comment